Janux Therapeutics
JANX
176 hedge funds and large institutions have $1.51B invested in Janux Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 80 increasing their positions, 54 reducing their positions, and 22 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 54
34% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $15.1M
3% less funds holding
Funds holding: 181 → 176 (-5)
3.56% less ownership
Funds ownership: 112.48% → 108.92% (-3.6%)
13% less capital inflows, than outflows
Capital inflows: $190M | Capital outflows: $218M
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46.6M |
| 2 |
BlackRock
New York
|
+$14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.8M |
| 4 |
OrbiMed
New York
|
+$11.9M |
| 5 |
Readystate Asset Management
Chicago,
Illinois
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$29.8M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$18M |
| 3 |
Perceptive Advisors
New York
|
-$17.9M |
| 4 |
Logos Global Management
San Francisco,
California
|
-$17.1M |
| 5 |
First Light Asset Management
Edina,
Minnesota
|
-$13.4M |
JANX Hedge Fund Activity: Q2 2025 in Review
176 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2025, worth a combined $1.51B — down 16% from $1.81B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of JANX and 18 opened new positions — a net loss of 4 holders — while 54 trimmed existing stakes and 80 added.
The largest buyer was Point72 Asset Management, adding an estimated $46.6M. The largest seller was Adage Capital Partners, cutting an estimated $29.8M.
- 176 institutional investors held Janux Therapeutics (JANX) as of Q2 2025, down from 181 in Q1 2025.
- Funds reported $1.51B of Janux Therapeutics stock for Q2 2025, down 16% quarter-over-quarter.
- 18 funds opened new Janux Therapeutics positions in Q2 2025 and 22 closed out, a net change of -4 holders.
- The largest Janux Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $46.6M added.
- The largest Janux Therapeutics seller in Q2 2025 was Adage Capital Partners, an estimated $29.8M sold.
Based on aggregated 13F filings for Q2 2025.